CAPR
Income statement / Annual
Last year (2023), Capricor Therapeutics, Inc.'s total revenue was $25.18 M,
an increase of 887.79% from the previous year.
In 2023, Capricor Therapeutics, Inc.'s net income was -$22.29 M.
See Capricor Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$25.18 M
|
$2.55 M
|
$244,898.00
|
$310,250.00
|
$1.01 M
|
$1.67 M
|
$1.37 M
|
$3.19 M
|
$3.78 M
|
$4.79 M
|
| Cost of Revenue |
$1.07 M |
$694,871.00 |
$245,697.00 |
$8.46 M |
$5.14 M |
$12.07 M |
$10.77 M |
$16.04 M |
$13.76 M |
$7.79 M |
| Gross Profit |
$24.11 M |
$1.85 M |
-$799.00 |
-$8.15 M |
-$4.14 M |
-$10.40 M |
-$9.40 M |
-$12.85 M |
-$9.98 M |
-$3.00 M |
| Gross Profit Ratio |
0.96 |
0.73 |
-0 |
-26.26 |
-4.12 |
-6.22 |
-6.87 |
-4.03 |
-2.64 |
-0.63 |
| Research and Development
Expenses |
$36.45 M
|
$21.82 M
|
$13.57 M
|
$8.46 M
|
$5.14 M
|
$12.07 M
|
$10.77 M
|
$16.04 M
|
$13.76 M
|
$7.79 M
|
| General & Administrative
Expenses |
$12.37 M
|
$10.43 M
|
$7.61 M
|
$5.54 M
|
$3.60 M
|
$4.93 M
|
$4.76 M
|
$4.93 M
|
$4.37 M
|
$3.02 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$12.37 M
|
$10.43 M
|
$7.61 M
|
$5.54 M
|
$3.60 M
|
$4.93 M
|
$4.76 M
|
$4.93 M
|
$4.37 M
|
$3.02 M
|
| Other Expenses |
$442,368.00 |
$190,582.00 |
$548,207.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$12.81 M |
$32.25 M |
$21.18 M |
$14.00 M |
$8.74 M |
$17.00 M |
$14.23 M |
$20.17 M |
$16.39 M |
$10.80 M |
| Cost And Expenses |
$49.26 M |
$32.25 M |
$21.18 M |
$14.00 M |
$8.74 M |
$17.00 M |
$14.23 M |
$20.17 M |
$16.39 M |
$10.80 M |
| Interest Income |
$1.73 M |
$521,534.00 |
$57,460.00 |
$32,943.00 |
$94,791.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
-$1.70 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$398,807.00 |
$344,665.00 |
$248,626.00 |
$200,505.00 |
| Depreciation &
Amortization |
$1.07 M
|
$694,871.00
|
$245,697.00
|
$143,890.00
|
$171,956.00
|
$157,652.00
|
$144,174.00
|
$134,637.00
|
$110,865.00
|
$41,896.00
|
| EBITDA |
-$23.01 M
|
-$29.16 M
|
-$20.69 M
|
-$13.55 M
|
-$7.56 M
|
-$15.17 M
|
-$12.72 M
|
-$18.33 M
|
-$12.50 M
|
-$5.97 M
|
| EBITDA Ratio |
-0.91 |
-11.84 |
-87 |
-44.23 |
-7.79 |
-9.17 |
-9.41 |
-5.32 |
-3.34 |
-1.25 |
| Operating Income Ratio
|
-0.96
|
-11.65
|
-85.5
|
-44.13
|
-7.7
|
-9.17
|
-9.41
|
-5.32
|
-3.34
|
-1.26
|
| Total Other
Income/Expenses Net |
$1.79 M
|
$677,851.00
|
$915,922.00
|
$32,943.00
|
$92,071.00
|
$135,991.00
|
$15.29 M
|
-$1.83 M
|
-$245,513.00
|
-$198,607.00
|
| Income Before Tax |
-$22.29 M |
-$29.02 M |
-$20.02 M |
-$13.66 M |
-$7.64 M |
-$15.19 M |
$2.43 M |
-$18.81 M |
-$12.86 M |
-$6.22 M |
| Income Before Tax Ratio
|
-0.89
|
-11.39
|
-81.76
|
-44.02
|
-7.6
|
-9.09
|
1.78
|
-5.9
|
-3.4
|
-1.3
|
| Income Tax Expense |
$0.00 |
-$677.85 |
-$613,412.00 |
-$176,833.00 |
-$264,027.00 |
$135,991.00 |
$254,633.00 |
$218,946.00 |
$137,761.00 |
$200,505.00 |
| Net Income |
-$22.29 M |
-$29.02 M |
-$19.41 M |
-$13.48 M |
-$7.38 M |
-$15.19 M |
$2.43 M |
-$18.81 M |
-$12.86 M |
-$6.22 M |
| Net Income Ratio |
-0.89 |
-11.38 |
-79.25 |
-43.45 |
-7.34 |
-9.09 |
1.78 |
-5.9 |
-3.4 |
-1.3 |
| EPS |
-0.83 |
-1.18 |
-0.84 |
-0.87 |
-1.99 |
-5.17 |
1 |
-10.14 |
-8.09 |
-5.31 |
| EPS Diluted |
-0.83 |
-1.18 |
-0.84 |
-0.87 |
-1.99 |
-5.17 |
0.9 |
-10.14 |
-8.09 |
-5.31 |
| Weighted Average Shares
Out |
$26.78 M
|
$24.55 M
|
$23.09 M
|
$15.57 M
|
$3.71 M
|
$2.94 M
|
$2.32 M
|
$1.86 M
|
$1.59 M
|
$1.17 M
|
| Weighted Average Shares
Out Diluted |
$26.78 M
|
$24.55 M
|
$23.09 M
|
$15.57 M
|
$3.71 M
|
$2.94 M
|
$2.68 M
|
$1.86 M
|
$1.59 M
|
$1.17 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
